Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured Osteoblasts.
From: Pediatric Research Institute, Cardinal Glennon Children’s Hospitals, St. Louis, Missouri 63110, USA.
The Journal of clinical endocrinology and metabolism
- Publish Date: Aug 2007
- ISSN: 0021-972X
- Volume: 92
- Issue: 8
- Pages: 2923-30
- Medium: Print
- Language: English
- Citation (JAMA): Cahill Richard A, Wenkert Deborah, Perlman Sharon A, et al. Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured Osteoblasts.. J. Clin. Endocrinol. Metab. Aug 2007;92:2923-30
Abstract
BACKGROUND: Hypophosphatasia (HPP) is a rare, heritable, metabolic bone disease due to deficient activity of the tissue-nonspecific isoenzyme of alkaline phosphatase. The infantile form features severe rickets often causing death in the first year of life from respiratory complications. There is no established medical treatment. In 1997, an 8-month-old girl with worsening and life-threatening infantile HPP improved considerably after marrow cell transplantation. OBJECTIVE: Our aim was to better understand and to advance these encouraging transplantation results. DESIGN: In 1999, based on emerging mouse transplantation models involving implanted donor bone fragments as well as osteoblast-like cells cultured from bone, we treated a 9-month-old girl suffering a similar course of infantile HPP. RESULTS: Four months later, radiographs demonstrated improved skeletal mineralization. Twenty months later, PCR analysis of adherent cells cultured from recipient bone suggested the presence of small amounts of paternal (donor) DNA despite the absence of hematopoietic engraftment. This patient, now 8 yr old (7 yr after transplantation), is active and growing, and has the clinical phenotype of the more mild, childhood form of HPP. CONCLUSIONS: Cumulative experience suggests that, after immune tolerance, donor bone fragments and marrow may provide precursor cells for distribution and engraftment in the skeletal microenvironment in HPP patients to form tissue-nonspecific isoenzyme of alkaline phosphatase-replete osteoblasts that can improve mineralization.
Mesh Headings (Keywords): Alkaline Phosphatase, Bone Marrow Transplantation, Bone Transplantation, Cell Differentiation, Cell Proliferation, Cells, Cultured, Child, Cytogenetics, DNA, Female, Humans, Hypercalcemia, Hypophosphatasia, Infant, Knee, Osteoblasts, Reverse Transcriptase Polymerase Chain Reaction, Stem Cells
Check for Full Text / PubMed Unique Identifier (PMID): 17519318
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.